ISB 2001
Alternative Names: ABBV-2001; ISB-2001; TREAT™ trispecific antibody - Ichnos SciencesLatest Information Update: 28 Dec 2025
At a glance
- Originator Ichnos Sciences
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Yes - Multiple myeloma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 10 Jul 2025 ISB 2001 licensed to Abbvie in North America, Europe, Japan, Hong Kong, Macau, Taiwan and China
- 12 Jun 2025 Updated efficacy and adverse event data from phase I trial in Multiple myeloma presented at the 30th Congress of the European Haematology Association 2025 (EHA-2025)